(Dallas, TX. – October 17, 2011) StockGuru Shines its Spotlight on Atlas Therapeutics Corporation (OTCBB: ATTH). The Company is the manufacturer of the innovative myostatin inhibitor, MYO-T12(R). On October 14, 2011, it announced that the Company sponsored Daniel “Ikemen” Gracie, of the world famous Gracie family, in his first fight in a new weight class (185) this past Saturday, October 15, 2011, at Bellator 54 in Atlantic City. The Company closed down twelve percent on October 14, 2011, at $0.2112, trading in a fifty-two week range of $2.00 – 0.15.
Gracie, a two-time World Champion, is part of the Gracie Family, who is often referred to as the First Family of MMA. He trained under Carlinhos Gracie and received his Black Belt at the age of 23. Gracie is a two-time World Champion in Brazilian Jiu-Jitsu and has garnered several other titles in his career. He is an MMA PRIDE and IFL veteran as well. Today, Gracie trains with Carlon Colker, M.D., who is widely regarded as one of the world’s foremost experts on wellness, physical performance, athletic enhancement, and performance nutrition and is the formulator of MYO-T12 (www.MYOT12.com). Thus far, Gracie has seen outstanding results from MYO-T12 and credits it to helping him make the weight-class move.
“I was introduced to MYO-T12 by Dr. Carlon Colker. He explained that this supplement will enable my body to shed fat and build muscle while training and cutting weight,” Gracie said. “I started immediately and saw the results just as fast. I was able to cut 20 pounds, build more muscle and build more strength. My workouts are more intense and the recovery time afterward is considerably shorter. I feel amazing and MYO-T12 is the ultimate supplement for me!”
JB Bernstein, CEO of Atlas Therapeutics, commented, “We are honored to be able to support Daniel Gracie. His accomplishments in his career are truly amazing, and his experience with MYO-T12 is yet another example of how superior performance and MYO-T12 go hand in hand.”
MYO-T12 is the world’s first clinically validated, myostatin-inhibiting dietary supplement. Myostatin is a protein naturally produced in our bodies which inhibits muscle growth and which increases as we age. MYO-T12 provides individuals a healthier method for building and maintaining lean muscle and reaching their fitness goals by reducing the body’s levels of myostatin to allow one’s natural growth hormones to perform at maximum efficiency. The supplement has been clinically proven to reduce average serum myostatin levels in the body by up to 46 percent within 12-18 hours after just one serving. For information, go to: www.MYOT12.com
ATLAS THERAPEUTICS CORPORATION
Atlas Therapeutics has acquired MYO-T12®, the world’s only clinically validated Myostatin modulator. Myostatin is a natural regulatory protein which inhibits muscle growth and recovery. MYO-T12® is manufactured to optimize biological activity and has the potential to redefine existing standards of physical enhancement. Atlas is focused on preserving and growing the existing brand identity of MYO-T12® by refining its technical profile, and designing and implementing a marketing and sales strategy to increase penetration of the product into the existing health and fitness community.
For more information on Atlas Therapeutics Corporation, visit www.AtlasTherapeutics.com.
The Atlas Therapeutics Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10042
Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
To view this StockGuru Spotlight, please visit: http://stockguru.com/category/latest-spotlights/
To get free alerts on this and other similar stocks, please register here:
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
John Pentony, Publisher, Stockguru.com
Tel: +1 469 252 3031
e-mail: [email protected]